PT-141 Reference Guide: Bremelanotide and Melanocortin Receptor Research

PT-141 (bremelanotide) is a cyclic heptapeptide derived from melanotan-II that is used in central-nervous-system melanocortin research. Its development history is unusual for a research peptide: PT-141 was identified as a metabolite of melanotan-II and developed as a separate research tool because it retained the CNS receptor activity of the parent compound while substantially reducing the pigmentation response associated with MC1R-driven melanogenesis.

In published research literature, PT-141 is studied primarily as a tool for probing MC3R and MC4R signaling in central pathways, with preclinical models focused on sexual response circuitry — the application that drove the FDA approval of bremelanotide for a specific clinical indication outside the scope of in-vitro research.

At a glance

Origin: derived from melanotan-II

PT-141 has the same cyclic core as melanotan-II but lacks the C-terminal amide. In early preclinical pharmacokinetic work, it was identified as a metabolite that retained much of the central melanocortin agonist activity of MT-II while showing a markedly weaker pigmentation response in matched assays. That dissociation — central receptor activity preserved, peripheral MC1R-mediated melanogenesis reduced — is what made PT-141 a distinct research tool rather than a redundant MT-II analogue.

For background on the pigmentation-focused melanocortin compounds, see Melanotan 1 vs Melanotan 2.

Melanocortin receptor pharmacology

The melanocortin system has five known receptors (MC1R through MC5R), each with distinct tissue distribution and signaling consequences:

• MC1R — skin and melanocytes; melanogenesis and pigmentation.
• MC2R — adrenal cortex; ACTH receptor (not meaningfully engaged by melanotan-family peptides).
• MC3R — hypothalamus and limbic system; energy homeostasis and sexual response circuitry.
• MC4R — central nervous system; appetite, energy balance, and CNS-mediated sexual response.
• MC5R — exocrine glands and adipose tissue.

PT-141 binds across the family but its functional research profile is dominated by MC3R and MC4R activity — the central receptors that mediate the behavioral and neuroendocrine effects of interest in CNS research.

What research models use it

• Central melanocortin signaling: hypothalamic neuron firing, MC4R receptor occupancy, and downstream cAMP response models.
• Preclinical sexual response circuitry:rodent models of proceptive and consummatory behavior driven by central melanocortin tone — the research lineage that informed bremelanotide's development.
• Appetite and energy balance: MC4R-mediated hypothalamic regulation; comparative work alongside other MC4R agonists and antagonists.
• Cardiovascular research: MC4R-mediated blood pressure effects in preclinical models — a known pharmacodynamic signal of central melanocortin agonism.

How PT-141 differs from melanotan-II

In matched preclinical work, the two compounds share central receptor activity but diverge on the pigmentation axis: MT-II produces a marked pigmentation response through MC1R, whereas PT-141 shows minimal pigmentation under comparable conditions. In research designs where pigmentation is a confound — for example, behavioral studies in pigmented strains where coat color changes would bias observer scoring — PT-141 is the preferred tool. Where pigmentation is the endpoint of interest, melanotan-II or melanotan-1 is more relevant.

Lab handling

Lyophilized PT-141 is stable at −20°C for typical research timeframes. It reconstitutes cleanly in bacteriostatic water without cosolvents. Standard practice applies: gentle swirling rather than shaking, aliquoting before freezing, and limiting freeze-thaw cycles.

For step-by-step reconstitution that applies to PT-141, see How to Reconstitute BPC-157. The procedure is shared across water-soluble research peptides; only the dilution math differs by vial size — see the Peptide Dilution Table for pre-computed values at 10 mg / 1 mL and 10 mg / 2 mL.

When to choose PT-141 in a research design

• Central MC3R/MC4R agonist arm: when the hypothesis depends on CNS melanocortin signaling rather than MC1R pigmentation.
• Pigmentation-controlled designs: models where a pigmentation response from melanotan-II would confound the endpoint.
• Comparative melanocortin work: paired with MT-1 (selective MC1R agonist) or MT-2 (broad agonist with strong pigmentation) to dissociate receptor contributions.

For Research Use Only. Information presented for laboratory and research applications. Not medical advice and not a substitute for qualified scientific judgment. Kalon Research does not provide identity, purity, or quality control documentation with shipments. Buyer assumes all responsibility.